CSIMarket Company Name, Ticker, Suppliers, else..
 
Leap Therapeutics Inc   (NASDAQ: LPTX)
Other Ticker:  
 
 
Price: $0.4010 $-0.01 -2.670%
Day's High: $0.419 Week Perf: 6.9 %
Day's Low: $ 0.38 30 Day Perf: 17.6 %
Volume (M): 260 52 Wk High: $ 4.79
Volume (M$): $ 104 52 Wk Avg: $1.95
Open: $0.38 52 Wk Low: $0.22



 Market Capitalization (Millions $) 17
 Shares Outstanding (Millions) 41
 Employees 18
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -69
 Cash Flow (TTM) (Millions $) -22
 Capital Exp. (TTM) (Millions $) 0

Leap Therapeutics Inc
Leap Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of immuno-oncology drugs. The company's primary goal is to discover and develop targeted therapies that have the potential to improve patient outcomes in cancers that are difficult to treat or have limited treatment options. Leap Therapeutics is known for its approach of combining therapies that target multiple pathways involved in cancer growth and survival. The company has a diverse pipeline of investigational drugs, including antibody-based therapies and combination therapies. Leap Therapeutics is headquartered in Cambridge, Massachusetts.


   Company Address: 47 Thorndike St, Suite B1-1 Cambridge 2141 MA
   Company Phone Number: 714-0360   Stock Exchange / Ticker: NASDAQ LPTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EBS        13.7% 
JNJ        2.73% 
MRK        0.78% 
PFE        0.57% 
REGN        3.25% 
VRTX   -0.16%    
• View Complete Report
   



Leap Therapeutics Inc

Pharmaceutical Giant's Impressive Growth Delights Investors Despite Operating Deficit

Leap Therapeutics Inc is a rising corporation in the Major Pharmaceutical Preparations sector that has recently announced its financial results for the first quarter of 2024. Despite reporting an operating deficit of $-14.825 million, the company has shown significant improvement compared to the same period last year when it reported an operating deficit of $-42.726 million.
One of the notable achievements of Leap Therapeutics Inc is the mitigation of its net loss. In the first quarter of 2024, the company managed to reduce the diminishing returns from the previous year, resulting in a shortfall of only $-13.820 million compared to $-41.863 million in the first quarter of 2023. This shows the company's commitment to improving its financial performance and taking steps to become more efficient.
Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.
Leap Therapeutics Inc

Leap Therapeutics Inc Faces Short-term Setbacks in Stock Value, But Demonstrates Remarkable Year-to-Date Performance



Leap Therapeutics Inc, a company trading on the NASDAQ, has experienced significant stock fluctuations over the past five trading days, with a decrease of -19.77% in its stock value. However, despite short-term setbacks, the company has demonstrated a remarkable year-to-date performance of 220.93%. Additionally, the stock is currently trading on the NASDAQ at a noteworthy 15.7% above its 52-week average. These figures raise questions about the potential impact of recent financial results on the company's future prospects.
Declining Stock Performance:
The recent decline in Leap Therapeutics Inc's stock value poses concerns for investors. A drop of -19.77% in just five trading days prompts apprehension about the factors influencing this downward trend. While short-term fluctuations do not always reflect the overall trajectory of a company, it is essential to analyze the underlying reasons for this decline to gauge its potential implications.
Leap Therapeutics Inc

Leap Therapeutics Inc Posts Narrower Operating Deficit of $-14.662 Million in Q2 2023, Signaling Positive Cost Optimization

Leap Therapeutics Inc, a company in the Major Pharmaceutical Preparations sector, recently published its operating deficit for the second quarter of 2023. The operating deficit for this period was $-14.662 million, which represents an increase compared to the second quarter of 2022, where the operating deficit was $-16.9 million. This is a crucial indicator for the future trajectory of Leap Therapeutics Inc (LPTX).
As an emerging growth business, Leap Therapeutics Inc is focused on building its revenue streams. In order to reach the next chapter of growth, it is essential for the company to operate economically. The recent decrease in operating deficit from $-17.024 million in the second quarter of 2022 to $-13.390 million is a positive sign that the company has succeeded in optimizing its costs.
Leap Therapeutics Inc

Leap Therapeutics Inc witnesses significant surge in outlays during the January-March 2023 quarter

The pharmaceutical industry is a highly competitive and complex market, with companies constantly striving to develop new and innovative drugs to meet the growing demands of consumers. The Major Pharmaceutical Preparations sector is one such area that has been closely watched by investors and industry analysts alike.
In recent times, the industry has been facing a period of rapid change, with new market entrants and advances in technology disrupting traditional business models. Against this backdrop, observers have begun scrutinizing the financial performance of companies in the sector, with the first quarter of 2023 now being the focus of attention.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com